Moderna's mRNA technology gained rapid validation as sales of its covid vaccine soared in 2021 and 2022, but we think the firm has yet to secure a narrow economic moat around its business, largely due ...

British pharmaceutical giant GlaxoSmithKline and rival Pfizer have agreed to end a lawsuit that alleged Pfizer's respiratory ...

The U.S. Food and Drug Administration has declined to approve Aldeyra Therapeutics' treatment for dry eye disease, the ...

It reported revenues of 38.41 million yuan in the first half of 2024 and a net loss of 903 million yuan, hit by falling ...

IDEAYA Biosciences, Inc.’s IDYA share price has surged by 10.70%, which has investors questioning if this is right time to sell.

Wall Street watches a company's quarterly report closely to understand as much as possible about its recent performance and what to expect going forward. Of course, one figure often stands out among ...

Pfizer delayed the announcement of its COVID-19 vaccine until after the 2020 election when it thought Donald Trump was defeated.

Abrysvo is now approved in the EU for adults aged 18 to 59 who are at increased risk of lower respiratory tract disease ...

A research team from the University of Minnesota Medical School has identified a strong predictor of ischemic stroke and dementia, a discovery that could lead to improved patient outcomes. The ...

Vaxcyte, Inc.'s stock fell 50% despite positive vaccine results. See how FDA uncertainty, competition, and Phase 3 delays ...

Shares in Moderna, Vaxcyte, Novavax and BioNTech all fell Monday after Peter Marks, head of the FDA office that reviews ...